TG Therapeutics, Inc. (TGTX)

Market Cap	6.07B -2.1%
Revenue (ttm)	700.35M +81.3%
Net Income	461.90M +1,079.8%
EPS	2.87 +1,105.5%
Shares Out	141.72M
PE Ratio	14.93
Forward PE	25.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,729,567
Open	43.02
Previous Close	43.03
Day's Range	42.26 - 44.65
52-Week Range	25.28 - 44.65
Beta	1.68
Analysts	Strong Buy
Price Target	51.80 (+20.86%)
Earnings Date	May 6, 2026

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 399
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Analyst Summary

According to 5 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price target is $51.8, which is an increase of 20.86% from the latest price.

Price Target

$51.8

(20.86% upside)

Analyst Consensus: Strong Buy